Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 6-7, 2011, Pages 504-514

  Naik, Shalini ^a   Lundberg, Johan ^b   Kumar, Ritesh ^b   Sjolin, Jan ^c   Jansen, Jeroen P ^a  

^a MAPI VALUES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Caspofungin; cost effectiveness; decision analytic model; liposomal amphotericin B; Sweden

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN;

ANALYTIC METHOD; ARTICLE; CHILL; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECONOMIC EVALUATION; FEVER; FLUSHING; HEALTH CARE UTILIZATION; HUMAN; LIFE EXPECTANCY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SWEDEN; TREATMENT RESPONSE; UNCERTAINTY; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEVER OF UNKNOWN ORIGIN; HUMANS; NEUTROPENIA; QUALITY OF LIFE; SURVIVAL ANALYSIS; SWEDEN;

EID: 79959260937     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.556145     Document Type: Article

References (25)

1. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 1993;167:1247-51.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007;20:133-63. (Pubitemid 46167771)
3. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-90. (Pubitemid 37168186)
4. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vincent JL. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004;10:550-5. (Pubitemid 38961581)
5. Maartens G, Wood MJ. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother 1991;28:13-22.
6. Bodey GP, Knotoyiannis DP, Lewis RE. Empiric antifungal therapy for persistently febrile neutropenic patients. Curr Treat Opt Infect Dis 2002;4:521-32.
7. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51. (Pubitemid 34194843)
8. Torfs K. Economic aspects of treatment for fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997;16:98-107. (Pubitemid 27095991)
9. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Eur Soc Clin Microbiol Infect Dis 2009;15:625-33.
10. Klingspor L, Tör nqvist E, Johansson A, Petrini B, Forsum U, Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004;36:52-5. (Pubitemid 38219772)
11. Böhme A, Ruhnke M, Buchheidt D, Karthaus M, Cornely O, Einsele H, et al. Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110.
12. Jorgensen JJ, Gotzsche PC, Johansen KH. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;1:CD004704.
13. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63. (Pubitemid 32295443)
14. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351:1391-402.
15. Prentice AG, Glasmacher A, Hobson RP, Schey S , Barnes RA, Donnelly JP, et al. Guidelines on the management of invasive fungal infection during therapy for haematological malignancy. London: British Committee for Standards in Haematology; 2010.
16. Bruynesteyn K, Gant V, McKenzie C, Pagliuca T, Poynton C, Kumar RN, Jansen JP. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007;78:532-9. (Pubitemid 46753596)
17. Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely O, Glasmacher A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008;87:311-9. (Pubitemid 351445291)
18. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;34:225-34. (Pubitemid 34438861)
19. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71. (Pubitemid 29114295)
20. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71.
21. Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113: 4179-87.
22. Swedish Lymphoma Registry. Svenska Lymfomregistret Rapport förår 2000-2006. Available from URL: http://www.ocsyd.se/VP- verksamhet/Kvalitetsreg/SvenskalymfomregistretRapport2000-2006.pdf (accessed date: December 2009).
23. Centre for Epidemiology, National Board of Health and Welfare. Cancer patient survival in Sweden 1980-2002. Sweden: National Board of Health and Welfare; 2004. Available at: http://www.socialstyrelsen.se/english/ statisticaldatabases/Sidor/cancersurvival-predictions2004.aspx (accessed date: December 2009).
24. Apoteket AB. Apoteket på två minuter. 2009. Available from URL: http://www.apoteket.se/privatpersoner/common/search.aspx?q=caspofungin
25. Prislista Akademiska sjukhuset i Uppsala (Uppsala University Hospital price list). Available from URL: http://www.externt9.lul.se/svn/akademiska09.xls (accessed date: December 2009).